Some GPs are quietly proving that targeted diet and lifestyle programmes can achieve similar results to Mounjaro, Wegovy and ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Novo Nordisk's Canadian patent for weight loss drug Ozempic is set to expire in January 2026. Dr. Justin Ezekowitz discusses generic competitors that may come.

A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side ...

Katy Perry is showing off her super-slim figure in a tiny bikini on a yacht, but fans think she's gotten too skinny.

The FDA approved semaglutide injections sold under the brand name Wegovy in 2021 as a treatment for chronic weight management ...

A new, late-stage clinical study shows disappointing results for Eli Lilly's weight loss pill Orforglipron. The experimental ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.

Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...